These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 30327454)

  • 1. [Cost-effectiveness of vaccines for the prevention of seasonal influenza in different age groups: a systematic review].
    Valcárcel Nazco C; García Lorenzo B; Del Pino Sedeño T; García Pérez L; Brito García N; Linertová R; Ferrer Rodríguez J; Imaz Iglesia I; Serrano Aguilar P
    Rev Esp Salud Publica; 2018 Oct; 92():. PubMed ID: 30327454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany.
    Scholz SM; Weidemann F; Damm O; Ultsch B; Greiner W; Wichmann O
    Value Health; 2021 Jan; 24(1):32-40. PubMed ID: 33431151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs and effectiveness of influenza vaccination: a systematic review.
    D'Angiolella LS; Lafranconi A; Cortesi PA; Rota S; Cesana G; Mantovani LG
    Ann Ist Super Sanita; 2018; 54(1):49-57. PubMed ID: 29616674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Net Costs Due to Seasonal Influenza Vaccination--United States, 2005-2009.
    Carias C; Reed C; Kim IK; Foppa IM; Biggerstaff M; Meltzer MI; Finelli L; Swerdlow DL
    PLoS One; 2015; 10(7):e0132922. PubMed ID: 26230271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe.
    Uhart M; Bricout H; Clay E; Largeron N
    Hum Vaccin Immunother; 2016 Sep; 12(9):2259-68. PubMed ID: 27166916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the U.K.
    Meier G; Gregg M; Poulsen Nautrup B
    J Med Econ; 2015; 18(9):746-61. PubMed ID: 25903831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model.
    Yang MC; Tan EC; Su JJ
    Hum Vaccin Immunother; 2017 Jan; 13(1):81-89. PubMed ID: 27624648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom.
    Thommes EW; Ismaila A; Chit A; Meier G; Bauch CT
    BMC Infect Dis; 2015 Oct; 15():465. PubMed ID: 26503131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extending the elderly- and risk-group programme of vaccination against seasonal influenza in England and Wales: a cost-effectiveness study.
    Baguelin M; Camacho A; Flasche S; Edmunds WJ
    BMC Med; 2015 Oct; 13():236. PubMed ID: 26459265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seasonal influenza vaccination of healthy working-age adults: a review of economic evaluations.
    Gatwood J; Meltzer MI; Messonnier M; Ortega-Sanchez IR; Balkrishnan R; Prosser LA
    Drugs; 2012 Jan; 72(1):35-48. PubMed ID: 22191794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral agents for influenza: a comparison of cost-effectiveness data.
    Lynd LD; Goeree R; O'Brien BJ
    Pharmacoeconomics; 2005; 23(11):1083-106. PubMed ID: 16277546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influenza vaccines in low and middle income countries: a systematic review of economic evaluations.
    Ott JJ; Klein Breteler J; Tam JS; Hutubessy RC; Jit M; de Boer MR
    Hum Vaccin Immunother; 2013 Jul; 9(7):1500-11. PubMed ID: 23732900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cost-effectiveness analysis of South Africa's seasonal influenza vaccination programme.
    Edoka I; Kohli-Lynch C; Fraser H; Hofman K; Tempia S; McMorrow M; Ramkrishna W; Lambach P; Hutubessy R; Cohen C
    Vaccine; 2021 Jan; 39(2):412-422. PubMed ID: 33272702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination of healthy children against seasonal influenza: a European perspective.
    Heikkinen T; Tsolia M; Finn A
    Pediatr Infect Dis J; 2013 Aug; 32(8):881-8. PubMed ID: 23856713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic benefits of inactivated influenza vaccines in the prevention of seasonal influenza in children.
    Salleras L; Navas E; Torner N; Prat AA; Garrido P; Soldevila N; Domínguez A
    Hum Vaccin Immunother; 2013 Mar; 9(3):707-11. PubMed ID: 23295894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic value of influenza vaccination.
    de Waure C; Veneziano MA; Cadeddu C; Capizzi S; Specchia ML; Capri S; Ricciardi W
    Hum Vaccin Immunother; 2012 Jan; 8(1):119-29. PubMed ID: 22251999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review of economic evaluations of seasonal influenza vaccination for the elderly population in the European Union.
    Shields GE; Elvidge J; Davies LM
    BMJ Open; 2017 Jun; 7(6):e014847. PubMed ID: 28601824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States.
    Clements KM; Chancellor J; Nichol K; DeLong K; Thompson D
    Value Health; 2011; 14(6):800-11. PubMed ID: 21914499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influenza vaccination in the Americas: Progress and challenges after the 2009 A(H1N1) influenza pandemic.
    Ropero-Álvarez AM; El Omeiri N; Kurtis HJ; Danovaro-Holliday MC; Ruiz-Matus C
    Hum Vaccin Immunother; 2016 Aug; 12(8):2206-2214. PubMed ID: 27196006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of influenza vaccination of healthy children.
    Salo H; Kilpi T; Sintonen H; Linna M; Peltola V; Heikkinen T
    Vaccine; 2006 Jun; 24(23):4934-41. PubMed ID: 16678945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.